Skip to main content
News & Announcements , Articles & Publications , Dr. Andrew Lewis

Dr. Andy Lewis Contributes to Roundtable with Contract Pharma on Growth Trends & Outlook in the OSD Manufacturing Market

Hexagons with Quotient Sciences logo

The global OSD contract manufacturing market is projected to grow, however, the sector faces challenges and is constantly evolving.

According to industry experts, trends set to shape the industry include advancement in drug delivery technologies, the increasing focus on personalized medicine, an emphasis on sustainability, and consolidation within the CDMO sector, but by far the most pertinent change-maker on everybody’s radar is the rise of AI.

Dr. Andrew Lewis, Chief Scientific Officer, contributes to the roundtable conversation with Contract Pharma, adding, "The FDA reported that in 2021, it saw more than 100 drug and biologic application submissions containing elements of AI or machine learning (ML) used in the development process."

"The earliest applications of AI in the pharmaceutical industry were in drug discovery," says Lewis. "Now, applications are being found in almost every function throughout development—from report writing and investigation of quality events, to manufacturing process control and facility management."

Read the full article, OSD Manufacturing Market: Growth Trends & Outlook, on the Contract Pharma website.

Latest news from Quotient Sciences

More News
News & Announcements, Articles & Publications, commercial manufacturing, Dr. Helen Baker, Dr. Richard Castledine Dr. Helen Baker and Dr. Richard Castledine contribute to Pharmaceutical Technology's 'Poor API Quality Threatens a Healthy Supply' By: Dr. Helen Baker and Dr. Richard Castledine
Read More
News & Announcements, Articles & Publications, Thierry Van Nieuwenhove Thierry Van Nieuwenhove on the Future of CDMO Partnerships By: Thierry Van Nieuwenhove
Read More
News & Announcements, Translational Pharmaceutics®, Articles & Publications BioPharm International interviews Helen Baker about how Quotient Sciences is optimizing drug development
Read More
Get in touch
Humanity can't afford to wait, so neither can we.